Elevated plasma TFPI activity causes attenuated TF-dependent thrombin generation in early onset preeclampsia

Summary

Early onset preeclampsia (EOP) is a pregnancy-specific proinflammatory disorder that is characterised by competing thrombotic and bleeding risks. It was the aim of this study to characterise thrombin generation, a major determinant of thrombotic and bleeding risk, in order to better understand the haemostatic balance in patients with EOP. Patients with EOP were recruited at the Rotunda Hospital, Dublin. Twenty-six cases of EOP were recruited over a 21-month period, out of 15,299 deliveries at the Rotunda. Blood samples were collected into sodium citrate plus corn trypsin inhibitor anticoagulated vacutainers, platelet-poor plasma was prepared, and calibrated automated thrombography was used to assess thrombin generation. Results were compared to age and sex-matched non-pregnant controls (n=13) and age-and gestation-matched pregnant controls (n=20). The rate and extent of thrombin generation triggered by low-dose tissue factor (TF) was significantly reduced in patients with EOP compared to pregnant controls, most significantly in cases of severe EOP. EOP patients displayed a trend towards an increased response to endogenous activated protein C and thrombomodulin relative to pregnant controls. Plasma tissue factor pathway inhibitor (TFPI) activity was increased in EOP patients. Inhibition of TFPI abolished the attenuation of thrombin generation stimulated by low-dose TF. In conclusion, patients with EOP are characterised by an attenuated coagulation response characterised by reduced thrombin generation stimulated by low-dose TF and elevated plasma TFPI activity. These changes in coagulation may modulate thrombotic risk and bleeding risk in patients with EOP.

Keywords

Pregnancy - tissue factor - tissue factor pathway inhibitor

• References

• 1 Hypertension in Pregnancy. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. 2014 Available at: http://www.acog.org/Resources-And-Publications/Task-Force-and-Work-Group-Reports/Hypertension-in-Pregnancy
• 2 Spong CY, Mercer BM, D’Alton M. et al. Timing of indicated late-preterm and early-term birth. Obstet Gynecol 2011; 118: 323-333.
• 3 Jacobsen AF, Skjeldestad FE, Sandset PM. Ante- and postnatal risk factors of venous thrombosis: a hospital-based case-control study. J Thromb Haemost 2008; 06: 905-912.
• 4 Kevane B, Donnelly J, D’Alton M. et al. Risk factors for pregnancy-associated venous thromboembolism: a review. J Perinat Med 2014; 42: 417-425.
• 5 Raymond D, Peterson E. A critical review of early-onset and late-onset pre-eclampsia. Obstet Gynecol Surv 2011; 66: 497-506.
• 6 Verlohren S, Herraiz I, Lapaire O. et al. The sFlt-1/PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol 2012; 206 (58) e1-8.
• 7 Zhang Z, Gao Y, Zhang L. et al. Alterations of IL-6, IL-6R and gp130 in early and late onset severe preeclampsia. Hypertens Pregn 2013; 32: 270-280.
• 8 Lisonkova S, Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am J Obstet Gynecol 2013; 209: 544 e1-e12.
• 9 Tranquilli AL, Brown MA, Zeeman GG. et al. The definition of severe and early-onset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Pregn Hypertens 2013; 03: 44-47.
• 10 https://www.nice.org.uk/guidance/cg107/resources/hypertension-in-pregnancy-diagnosis-and-management-35109334009285
• 11 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
• 12 Spronk HM, Dielis AW, De Smedt E. et al. Assessment of thrombin generation II: Validation of the Calibrated Automated Thrombogram in platelet-poor plasma in a clinical laboratory. Thromb Haemost 2008; 100: 362-364.
• 13 Rosenkranz A, Hiden M, Leschnik B. et al. Calibrated automated thrombin generation in normal uncomplicated pregnancy. Thromb Haemost 2008; 99: 331-337.
• 14 Macey MG, Bevan S, Alam S. et al. Platelet activation and endogenous thrombin potential in pre-eclampsia. Thrombosis Res 2010; 125: e76-81.
• 15 Luddington R, Baglin T. Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition. J Thromb Haemost 2004; 02: 1954-1959.
• 16 Wood JP, Ellery PE, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood 2014; 123: 2934-2943.
• 17 Dahm A, Van Hylckama Vlieg A, Bendz B. et al. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003; 101: 4387-4392.
• 18 Abdel Gader AM, Al-Mishari AA, Awadalla SA. et al. Total and free tissue factor pathway inhibitor in pregnancy hypertension. Intern J Gynaecol Obstet 2006; 95: 248-253.
• 19 Hillman S, Chant I, Gu M. et al. Tissue pathway factor inhibitor (TFPI) activity is elevated in pregnant patients at 20 weeks gestation who subsequently develop preeclampsia. Thromb Haemost 2009; 101: 778-780.
• 20 Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation 2011; 123: 2856-2869.
• 21 Aharon A, Katzenell S, Tamari T, Brenner B. Microparticles bearing tissue factor and tissue factor pathway inhibitor in gestational vascular complications. J Thromb Haemost 2009; 07: 1047-1050.
• 22 Edstrom CS, Calhoun DA, Christensen RD. Expression of tissue factor pathway inhibitor in human fetal and placental tissues. Early Human Develop 2000; 59: 77-84.
• 23 Kozic JR, Benton SJ, Hutcheon JA. et al. Abnormal liver function tests as predictors of adverse maternal outcomes in women with preeclampsia. J Obstet Gynaecol Canada 2011; 33: 995-1004.
• 24 Munazza B, Raza N, Naureen A. et al. Liver function tests in preeclampsia. J Ayub Med Coll 2011; 23: 3-5.
• 25 Thangaratinam S, Koopmans CM, Iyengar S. et al. Accuracy of liver function tests for predicting adverse maternal and fetal outcomes in women with pre-eclampsia: a systematic review. Acta Obstet Gynecol Scand 2011; 90: 574-585.
• 26 Brummel-Ziedins KE, Vossen CY, Butenas S, Mann KG, Rosendaal FR. Thrombin generation profiles in deep venous thrombosis. J Thromb Haemost 2005; 03: 2497-2505.
• 27 Campo G, Pavasini R, Pollina A. et al. Thrombin generation assay: a new tool to predict and optimize clinical outcome in cardiovascular patients?. Blood Coagul Fibrinol 2012; 23: 680-687.
• 28 Rugeri L, Quelin F, Chatard B. et al. Thrombin generation in patients with factor XI deficiency and clinical bleeding risk. Haemophilia 2010; 16: 771-777.